Vanguard Global Advisers
AMLX icon

Vanguard Global Advisers’s Amylyx Pharmaceuticals AMLX Stock Holding History

Vanguard Global Advisers’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$859K Hold
47,851
– – ﹤0.01% 1832
2026
Q1 		$665K Buy
+47,851
New +$673K ﹤0.01% 1898

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Global Advisers's AMLX Position: Q2 2026 in Review

Vanguard Global Advisers held its Amylyx Pharmaceuticals (AMLX) position steady in Q2 2026 at 47,851 shares worth $859K. The position accounts for ﹤0.01% of the portfolio, ranked #1832.

Vanguard Global Advisers first reported a position in AMLX in Q1 2026 and has held it in 2 quarters since. 205 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Vanguard Global Advisers held 47,851 shares of Amylyx Pharmaceuticals worth $859K as of Q2 2026.
  • Vanguard Global Advisers left its Amylyx Pharmaceuticals share count unchanged in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1832 holding.
  • Vanguard Global Advisers first reported a position in Amylyx Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 205 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.